Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation
Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen
Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen
View: Text | PDF
Research Article Cardiology Immunology

Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation

  • Text
  • PDF
Abstract

Extracellular vesicle–mediated interorgan communication represents a promising frontier in transplant immunology; however, its role in cardiac allograft rejection remains poorly characterized. We performed proteomic profiling of plasma-derived extracellular vesicles in a rat heterotopic heart transplantation model and identified a distinct liver-predominant protein signature during acute rejection, with antithrombin III (ATIII) emerging as a top candidate. Functional validation revealed that pharmacological extracellular vesicle inhibition intensified systemic and intragraft inflammation, whereas adeno-associated virus–mediated silencing of hepatic ATIII directly accelerated allograft rejection. Conversely, adeno-associated virus–mediated hepatocyte-specific ATIII overexpression attenuated rejection pathology, reduced immune cell recruitment, and markedly prolonged median graft survival. This protective effect was achieved without evidence of coagulopathic complications, indicating an immunomodulatory mechanism beyond ATIII’s canonical anticoagulant function. Mechanistically, ATIII overexpression was associated with upregulation of heme oxygenase-1 (HO-1) in the liver and suppression of proinflammatory cytokine expression in the graft. These findings highlight hepatocyte-derived extracellular vesicles as important mediators of a liver-heart signaling axis in transplant rejection and further implicate the protein ATIII as a contributor to this axis. Our study reveals a therapeutically targetable liver-heart signaling axis in transplant rejection, whereby enhancing liver-derived ATIII or its downstream pathways (such as HO-1) could attenuate acute cardiac allograft rejection.

Authors

Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen

×

Figure 3

Mapping tissue origins of plasma EV proteins in cardiac allograft rejection.

Options: View larger image (or click on image) Download as PowerPoint
Mapping tissue origins of plasma EV proteins in cardiac allograft reject...
(A) Polar bar chart displays the count of tissue-enhanced DEPs identified in allogeneic recipients. (B) Protein-protein interaction analysis of tissue-specific proteins altered in allogeneic recipients. Node colors indicate corresponding tissue origins. (C) Experimental scheme illustrating the in vivo EV tracing strategy. AAV8-TBG-palm-mCherry, expressing a hepatocyte-specific membrane-localized mCherry fluorescent protein, was administered to mice via tail vein injection. Mice were then maintained for 4 weeks to allow for hepatocyte transduction and subsequent mCherry-labeled EV production and systemic distribution. Cardiac tissues were harvested at the experimental endpoint for confocal analysis. (D) Representative confocal images demonstrating mCherry fluorescence in the myocardium of AAV8-TBG-palm-mCherry–injected mice. White arrows indicate liver-derived mCherry-positive EVs distributed within the cardiac parenchyma. The panel on the right provides a high-magnification view (magnified from the boxed area) with an orthogonal projection (x-z and y-z planes), confirming the internalization and spatial localization of hepatic EVs within the myocardial tissue. Images are representative of 3 mice per group (n = 3). Scale bars: 200 μm (left panel) and 5 μm (right magnified view). (E) Functional enrichment in liver. GO biological process (BP) analysis of DEPs enhanced in hepatic tissue. (F) Integrated network of liver-enhanced proteins and associated signaling cascades (blood coagulation) dysregulated in allograft recipients. Label colors in B and F indicate protein expression changes in the Allo group compared with the sham group: blue denotes downregulated proteins, red denotes upregulated proteins. Proteomic data in A, B, E, and F represent n = 3 independent biological replicates. Enrichment P values were calculated by hypergeometric test and Benjamini-Hochberg–adjusted FDR < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts